Procter & Gamble Cuts Fiscal-Year Guidance After 3Q Sales Decline

Dow Jones
04-24
 

By Kelly Cloonan

 

Procter & Gamble lowered its fiscal-year outlook after posting lower sales in the third quarter amid a challenging consumer environment.

The consumer-products company logged a profit of $3.77 billion, or $1.54 a share, in the quarter ended March 31, compared with $3.75 billion, or $1.52 a share, a year earlier.

Adjusted earnings per share were $1.54. Analysts polled by FactSet expected $1.52 a share.

Sales fell 2%, to $19.78 billion, behind analysts' forecasts for $20.15 billion, according to FactSet.

The top line was up 1% on an organic basis, driven by higher pricing. Mix and organic volume had a neutral effect on sales, the company said.

Organic sales gains in the company's beauty, grooming and healthcare segments offset a slight decline in its baby- and feminine-care unit. Organic volume and sales were flat for the company's fabric- and home-care segment.

P&G's gross margin fell during the quarter as unfavorable mix, product reinvestments, and higher commodity costs more than offset benefits from productivity savings and higher prices.

Chief Executive Jon Moeller said the quarter provided a challenging and volatile consumer and geopolitical environment.

For fiscal 2025, the company now expects sales to be roughly flat compared with the prior year, down from prior guidance for growth of 2% to 4%.

The company expects organic sales growth of about 2%, down from previous expectations for 3% to 5% growth.

The company also lowered its guidance for net earnings-per-share growth to a range of 6% to 8% from between 10% to 12%.

Moeller said the outlook adjustments reflect underlying market conditions.

 

Write to Kelly Cloonan at kelly.cloonan@wsj.com

 

(END) Dow Jones Newswires

April 24, 2025 07:00 ET (11:00 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10